Nasdaq Delisting Notice Hits InMed Over $1.08M Equity Shortfall
INM has more than doubled off its 52-week low of $0.575.
Summary
InMed received a Nasdaq delisting notice for failing to maintain the minimum $2.5M shareholders' equity requirement. The company expects the pending Mentari merger to restore compliance, but the merger has not yet closed.
Key Events · Legal and Risk Events · INM
-
Nasdaq Delisting Notice Received
On September 16, 2026, Nasdaq notified InMed that its shareholders' equity of $1,075,007 is below the $2,500,000 minimum required under Listing Rule 5550(b)(1).
-
Compliance Plan Deadline
InMed has 45 calendar days (until November 2, 2026) to submit a plan to regain compliance, and may be granted up to 180 days (until March 15, 2027) to evidence compliance.
-
Merger Expected to Restore Compliance
The company expects the pending Mentari reverse merger to restore compliance, citing approximately $490 million in expected gross proceeds from the pre-closing financing.
-
Delisting Risk Remains
The merger is expected to close in Q4 2026 subject to shareholder approval; if the plan is not accepted or compliance is not regained, InMed's shares could be delisted.
Analysis · INM · Life Sciences
Nasdaq has formally notified InMed that its shareholders' equity of $1,075,007 falls below the $2,500,000 minimum required for continued listing on the Nasdaq Capital Market. The company has 45 days to submit a compliance plan and may receive up to 180 days to regain compliance. InMed expects the pending reverse merger with Mentari Therapeutics to restore compliance, citing approximately $490 million in expected gross proceeds from the pre-closing financing. However, the merger is not yet closed and remains subject to shareholder approval, leaving delisting risk if the transaction fails or is delayed.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 974 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INM was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.58 to $2.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.